메뉴 건너뛰기




Volumn 33, Issue 6, 2010, Pages 455-461

Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers

Author keywords

Adverse reactions; Becaplermin; Benefit risk assessment; Cost effectiveness; Diabetic foot, treatment; Diabetic foot ulcer; Peripheral nerve disorders; Therapeutic use; Treatment

Indexed keywords

BECAPLERMIN; CARBOXYMETHYLCELLULOSE; PLACEBO;

EID: 77952815052     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11534570-000000000-00000     Document Type: Review
Times cited : (96)

References (44)
  • 2
    • 43049098631 scopus 로고    scopus 로고
    • The diabetic foot: Grand overview, epide-miology and pathogenesis
    • Boulton AJM. The diabetic foot: grand overview, epide-miology and pathogenesis. Diabetes Metab Res Rev 2008; 24 Suppl. 1: S3-6
    • (2008) Diabetes Metab Res Rev , vol.24 , Issue.SUPPL. 1
    • Boulton, A.J.M.1
  • 4
    • 34547771648 scopus 로고    scopus 로고
    • The diabetic foot: Established and emerging treatments
    • Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-238
    • (2007) Acta Clin Belg , vol.62 , pp. 230-238
    • Papanas, N.1    Maltezos, E.2
  • 5
    • 0345654302 scopus 로고    scopus 로고
    • Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings
    • Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162
    • (1999) Diabetes Care , vol.22 , pp. 157-162
    • Reiber, G.E.1    Vileikyte, L.2    Boyko, E.J.3
  • 6
    • 2642529778 scopus 로고    scopus 로고
    • Epidemiology of diabetic foot ulcers and complications: Evidence for prevention
    • Williams R, Herman W, Kinmoth AL, et al., editors Chichester: Wiley
    • Reiber GE, Ledoux WR. Epidemiology of diabetic foot ulcers and complications: evidence for prevention. In: Williams R, Herman W, Kinmoth AL, et al., editors. The evidence base for diabetes care. Chichester: Wiley, 2002: 641-665
    • (2002) The Evidence Base for Diabetes Care , pp. 641-665
    • Reiber, G.E.1    Ledoux, W.R.2
  • 7
    • 4544221049 scopus 로고    scopus 로고
    • The diabetic foot: From art to science the 18th Camillo Golgi lecture
    • Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-1353
    • (2004) Diabetologia , vol.47 , pp. 1343-1353
    • Boulton, A.J.M.1
  • 8
    • 47849085516 scopus 로고    scopus 로고
    • Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
    • Papanas N, Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 2008; 3: 233-240
    • (2008) Clin Interv Aging , vol.3 , pp. 233-240
    • Papanas, N.1    Maltezos, E.2
  • 9
    • 77949871954 scopus 로고    scopus 로고
    • A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers
    • Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008; 2: 1-12
    • (2008) Biologics , vol.2 , pp. 1-12
    • Fang, R.C.1    Galiano, R.D.2
  • 10
    • 0032164008 scopus 로고    scopus 로고
    • Use of Regranex gel for diabetic foot ulcers
    • Piascik P. Use of Regranex gel for diabetic foot ulcers. J Am Pharm Assoc 1998; 38: 628-630
    • (1998) J Am Pharm Assoc , vol.38 , pp. 628-630
    • Piascik, P.1
  • 11
    • 33847005383 scopus 로고    scopus 로고
    • Growth factors in the treatment of diabetic foot ulcers: New technologies any promises?
    • Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem Wounds 2007; 6: 37-53
    • (2007) Int J Low Extrem Wounds , vol.6 , pp. 37-53
    • Papanas, N.1    Maltezos, E.2
  • 12
    • 77952849087 scopus 로고    scopus 로고
    • US prescribing information for Regranex [online] [Accessed 2010 Mar 16]
    • US prescribing information for Regranex [online]. Available from URL: http://www.regranex.com/Prescribing%20Info. php [Accessed 2010 Mar 16]
  • 14
    • 0028873980 scopus 로고
    • Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
    • Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71-81
    • (1995) J Vasc Surg , vol.21 , pp. 71-81
    • Steed, D.L.1
  • 15
    • 0031734833 scopus 로고    scopus 로고
    • Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III randomized placebo-controlled double-blind study
    • Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827
    • (1998) Diabetes Care , vol.21 , pp. 822-827
    • Wieman, T.J.1    Smiell, J.M.2    Su, Y.3
  • 16
    • 0032399279 scopus 로고    scopus 로고
    • Effect of so-dium carbomethylcellulose aqueous-based gel versus beca-plermin gel in patients with non-healing lower extremity diabetic ulcers
    • D'Hemercourt PA, Smiell JM, Karim MR. Effect of so-dium carbomethylcellulose aqueous-based gel versus beca-plermin gel in patients with non-healing lower extremity diabetic ulcers. Wounds 1998; 10: 69-75
    • (1998) Wounds , vol.10 , pp. 69-75
    • D'Hemercourt, P.A.1    Smiell, J.M.2    Karim, M.R.3
  • 17
    • 0033945354 scopus 로고    scopus 로고
    • Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of safety
    • Embil JM, Papp K, Sibblad G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of safety. Wound Rep Reg 2000; 8: 162-168
    • (2000) Wound Rep Reg , vol.8 , pp. 162-168
    • Embil, J.M.1    Papp, K.2    Sibblad, G.3
  • 18
    • 33646115207 scopus 로고    scopus 로고
    • Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers
    • Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Rep Reg 2005; 13: 531-536
    • (2005) Wound Rep Reg , vol.13 , pp. 531-536
    • Margolis, D.J.1    Bartus, C.2    Hoffstad, O.3
  • 19
    • 57949103536 scopus 로고    scopus 로고
    • Which is the better option: Recombinant human PDGF-BB 0.01% gel or standard wound care in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
    • Bhansali A, Venkatesh S, Dutta P, et al. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast? Diabetes Res Clin Pract 2009; 83: e13-6
    • (2009) Diabetes Res Clin Pract , vol.83
    • Bhansali, A.1    Venkatesh, S.2    Dutta, P.3
  • 20
    • 22244469421 scopus 로고    scopus 로고
    • Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: A randomized, multicenter, double-blind, placebo-controlled study in India
    • Hardikar JV, Reddy YC, Bung DD, et al. Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India. Wounds 2005; 17: 141-152
    • (2005) Wounds , vol.17 , pp. 141-152
    • Hardikar, J.V.1    Reddy, Y.C.2    Bung, D.D.3
  • 22
    • 0034529470 scopus 로고    scopus 로고
    • Risk factors for delayed healing of neuropathic diabetic foot ulcers
    • Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers. Arch Dermatol 2000; 136: 1531-1535
    • (2000) Arch Dermatol , vol.136 , pp. 1531-1535
    • Margolis, D.J.1    Kantor, J.2    Santanna, J.3
  • 24
    • 13444292199 scopus 로고    scopus 로고
    • Healing Diabetic Neuropathic Foot Ulcers: Are We Getting Better?
    • Margolis DJ, Allen-Taylor L, Hoffstad O, et al. Healing diabetic neuropathic foot ulcers: are we getting better? Diabet Med 2005; 22: 172-176
    • (2005) Diabet Med , vol.22 , pp. 172-176
    • Margolis, D.J.1    Allen-Taylor, L.2    Hoffstad, O.3
  • 25
    • 0035985215 scopus 로고    scopus 로고
    • Transforming growth factor-beta 1, 2, 3 and receptor type i and II in diabetic foot ulcers
    • Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-447
    • (2002) Diabet Med , vol.19 , pp. 440-447
    • Jude, E.B.1    Blakytny, R.2    Bulmer, J.3
  • 26
    • 0034028713 scopus 로고    scopus 로고
    • Lack of insulin-like growth factor 1 (IGF-1) in the basal keratino-cyte layer of diabetic skin and diabetic foot ulcers
    • Blakytny R, Jude EB, Martin Gibson J, et al. Lack of insulin-like growth factor 1 (IGF-1) in the basal keratino-cyte layer of diabetic skin and diabetic foot ulcers. J Pathol 2000; 190: 589-594
    • (2000) J Pathol , vol.190 , pp. 589-594
    • Blakytny, R.1    Jude, E.B.2    Martin Gibson, J.3
  • 27
    • 0035745275 scopus 로고    scopus 로고
    • Effect of glycation on basic fibroblast growth factor-induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes
    • Duraisamy Y, Slevin M, Smith N, et al. Effect of glycation on basic fibroblast growth factor-induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001; 4: 277-288
    • (2001) Angiogenesis , vol.4 , pp. 277-288
    • Duraisamy, Y.1    Slevin, M.2    Smith, N.3
  • 28
    • 0037225778 scopus 로고    scopus 로고
    • Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control
    • Black E, Vibe-Pedersen J, Jorgensen LN, et al. Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control. Arch Surg 2003; 138: 34-40
    • (2003) Arch Surg , vol.138 , pp. 34-40
    • Black, E.1    Vibe-Pedersen, J.2    Jorgensen, L.N.3
  • 29
    • 33744780764 scopus 로고    scopus 로고
    • The molecular biology of chronic wounds and delayed healing in diabetes
    • Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608
    • (2006) Diabet Med , vol.23 , pp. 594-608
    • Blakytny, R.1    Jude, E.2
  • 30
    • 2642543938 scopus 로고    scopus 로고
    • Wound healing and treatments for people with diabetic foot ulcers
    • Jeffcoate W, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20 Suppl. 1: S78-89
    • (2004) Diabetes Metab Res Rev , vol.1 , Issue.SUPPL.
    • Jeffcoate, W.1    Price, P.2    Harding, K.G.3
  • 31
    • 27744448125 scopus 로고    scopus 로고
    • Wound healing and its impairment in the dia-betic foot
    • Falanga V. Wound healing and its impairment in the dia-betic foot. Lancet 2005; 366: 1736-1743
    • (2005) Lancet , vol.366 , pp. 1736-1743
    • Falanga, V.1
  • 32
    • 0032720053 scopus 로고    scopus 로고
    • Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies
    • Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg 1999; 7: 335-346
    • (1999) Wound Rep Reg , vol.7 , pp. 335-346
    • Smiell, J.M.1    Wieman, T.J.2    Steed, D.L.3
  • 33
    • 0034505166 scopus 로고    scopus 로고
    • The cost-effective-ness of treating diabetic lower extremity ulcers with beca-plermin (Regranex): A core model with an application using Swedish cost data
    • Persson U, Willis M, Odegaard K, et al. The cost-effective-ness of treating diabetic lower extremity ulcers with beca-plermin (Regranex): a core model with an application using Swedish cost data. Val Health 2000; 3 Suppl. 1: S39-46
    • (2000) Val Health , vol.3 , Issue.SUPPL. 1
    • Persson, U.1    Willis, M.2    Odegaard, K.3
  • 34
    • 56549089497 scopus 로고    scopus 로고
    • The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel
    • Ghatnekar O, Persson U, Willis M, et al. The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel. J Drug Assess 2000; 3: 243-251
    • (2000) J Drug Assess , vol.3 , pp. 243-251
    • Ghatnekar, O.1    Persson, U.2    Willis, M.3
  • 35
    • 0034922872 scopus 로고    scopus 로고
    • Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries
    • Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19: 767-778
    • (2001) Pharmacoeconomics , vol.19 , pp. 767-778
    • Ghatnekar, O.1    Persson, U.2    Willis, M.3
  • 36
    • 0035074207 scopus 로고    scopus 로고
    • Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis
    • DOI 10.1046/j.1524-4725.2001.00280.x
    • Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001; 27: 347-351 (Pubitemid 32290859)
    • (2001) Dermatologic Surgery , vol.27 , Issue.4 , pp. 347-351
    • Kantor, J.1    Margolis, D.J.2
  • 37
    • 0036814116 scopus 로고    scopus 로고
    • Cost-effective management of recalcitrant diabetic foot ulcers
    • Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002; 19: 483-491
    • (2002) Clin Podiatr Med Surg , vol.19 , pp. 483-491
    • Albert, S.1
  • 38
    • 8144226304 scopus 로고    scopus 로고
    • Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers
    • Sibbald RG, Torrance G, Hux M, et al. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003; 49: 76-84
    • (2003) Ostomy Wound Manage , vol.49 , pp. 76-84
    • Sibbald, R.G.1    Torrance, G.2    Hux, M.3
  • 39
    • 77952793213 scopus 로고    scopus 로고
    • Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer
    • Lantis II JC, Boone D, Gendics C, et al. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care 2009; 22: 167-171
    • (2009) Adv Skin Wound Care , vol.22 , pp. 167-171
    • Lantis Ii, J.C.1    Boone, D.2    Gendics, C.3
  • 40
    • 0031713762 scopus 로고    scopus 로고
    • Clinical safety of becaplermin (rhPDGF-BB) gel
    • Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Am J Surg 1998; 176 Suppl. 2A: 68-73S
    • (1998) Am J Surg , vol.176 , Issue.SUPPL. 2A
    • Smiell, J.M.1
  • 41
    • 77952796728 scopus 로고    scopus 로고
    • Efficacy and safety of recombinant human platelet-derived growth factor gel for diabetic neuropathic foot ulcers: A systematic review
    • Shi J, Chen T, Tian H. Efficacy and safety of recombinant human platelet-derived growth factor gel for diabetic neuropathic foot ulcers: a systematic review. Diabetologia 2009; 52 Suppl. 1: A1157
    • (2009) Diabetologia , vol.52 , Issue.SUPPL. 1
    • Shi, J.1    Chen, T.2    Tian, H.3
  • 42
    • 85049141358 scopus 로고    scopus 로고
    • Update of safety review: follow-up to the March 27 [online] [Accessed 2009 Oct 7]
    • US FDA. Update of safety review: follow-up to the March 27, 2008, communication about the ongoing safety review of Regranex (becaplermin) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/DrugSafetyIn formationforHeathcareProfessionals/ucm072148.htm [Accessed 2009 Oct 7]
    • (2008) Communication about the Ongoing Safety Review of Regranex (Becaplermin)
    • Us, F.D.A.1
  • 43
    • 33750956014 scopus 로고    scopus 로고
    • Emerging drugs for diabetic foot ulcers
    • Petrova N, Edmonds M. Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs 2006; 11: 709-724
    • (2006) Expert Opin Emerg Drugs , vol.11 , pp. 709-724
    • Petrova, N.1    Edmonds, M.2
  • 44
    • 77952795360 scopus 로고    scopus 로고
    • Topical becaplermin: Cancer. Think twice before using it
    • Topical becaplermin: cancer. Think twice before using it. Rev Prescrire 2008; 28: 430
    • (2008) Rev Prescrire , vol.28 , pp. 430


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.